FDA Approves Cologuard Plus for Adults at Average Risk for CRC
The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.
Related Articles
Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium
A pooled analysis of 9548 HNC cases and 15,783 controls from the International Head and Neck Cancer Epidemiology consortium was conducted to assess the association…
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer
This randomized clinical trial investigates whether a single oral dose of cannabidiol improves scan-related anxiety in women with advanced breast cancer.
Welcome! You are invited to join a webinar: Skin VJSessions: Therapeutic Advances in PD-1 Refractory Skin Cancer. After registering, you will receive a confirmation email about joining the webinar.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Ways to Give to the ASH Foundation
Help move hematology forward with a charitable gift or pledge to the ASH Foundation. Your generous support enables the ASH Foundation to do more for…
Blood-Based Ageing Clock Shows Promise as a Clinical Tool
A groundbreaking study has developed a blood-based ageing clock capable of predicting biological age and providing insights into the ageing process. Read on to learn…
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
This randomized clinical trial evaluates whether the combination of lenvatinib plus ifosfamide and etoposide improves outcomes in children and young adults with relapsed osteosarcoma.
Updated results of the ANDROMEDA trial: daratumumab + CyBorD versus CyBorD alone in AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents the updated results of the ANDROMEDA trial (NCT03201965), a Phase III randomized global international…
von Hippel-Lindau syndrome-related congenital polycythemia and response to belzutifan
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Vanderbilt University Medical Center, Nashville,…
Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD
Drs Camidge and Redman discuss Dr Redman’s role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
